LAVURCHIN is a radiosensitizer of a new type that was discovered from marine organism-derived natural products.
At MT3, research and development with a focus on a new radiotherapy that utilizes the "radiosensitizer” is in progress. At present, it is at a clinical trial stage of drugs for veterinary use. Development is being conducted with the future goal of achieving a status of medicinal product for human use.
The following are R&D reports with regard to the radiosensitizer, LAVURCHIN.
This site has been created for the purpose of using LAVURCHIN properly by providing information related to LAVURCHIN
MT3, Inc. has paid close attention to the information on this site, but it does not guarantee the accuracy, safety, usefulness etc. of the contents, and also on this site and this site it is not responsible for any damage caused by using the information described.
Do you browse the site after agreeing to the above notes?
If you do not agree to notes on information provision, you can not view the site.
Excuse me, please close the page or end browsing with browser back